QULIPTA DIN 02533979
Health Canada record
| Active ingredient(s) | ATOGEPANT 10 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | N02CD07 ATOGEPANT |
| Original market date | 24-Mar-2023 |
| Current status date | 24-Mar-2023 |
| Source | Health Canada DPD |
Establishment licence of the holder
AbbVie Corporation — licence 101988, currently licensed, last inspection rating C (2023-07-18).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ATOGEPANT
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02533987 | QULIPTA | ABBVIE CORPORATION | Tablet | ATOGEPANT 30 MG | Marketed |
| 02533995 | QULIPTA | ABBVIE CORPORATION | Tablet | ATOGEPANT 60 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 29754 | 2022-12-22 | New Drug Submission (NDS) |
International API supply for ATOGEPANT
4 active FDA Drug Master Files.
Request a quote for QULIPTA